Skip to Content
You are currently on the new version of our website. Access the old version .
  • Review
  • Open Access

11 July 2023

18 Pages

Translating Molecular Biology Discoveries to Develop Targeted Cancer Interception in Barrett’s Esophagus

,
,
,
and
1
Department of Internal Medicine, University of Kansas Health System, Kansas City, KS 66160, USA
2
Department of Gastroenterology and Hepatology, University of Kansas Health System, Kansas City, KS 66160, USA
3
Center for Esophageal Diseases, Department of Medicine, Baylor University Medical Center, Dallas, TX 75246, USA
4
Center for Esophageal Research, Baylor Scott & White Research Institute, Dallas, TX 75246, USA

Abstract

Esophageal adenocarcinoma (EAC) is a rapidly increasing lethal tumor. It commonly arises from a metaplastic segment known as Barrett’s esophagus (BE), which delineates the at-risk population. Ample research has elucidated the pathogenesis of BE and its progression from metaplasia to invasive carcinoma; and multiple molecular pathways have been implicated in this process, presenting several points of cancer interception. Here, we explore the mechanisms of action of various agents, including proton pump inhibitors, non-steroidal anti-inflammatory drugs, metformin, and statins, and explain their roles in cancer interception. Data from the recent AspECT trial are discussed to determine how viable a multipronged approach to cancer chemoprevention would be. Further, novel concepts, such as the repurposing of chemotherapeutic drugs like dasatinib and the prevention of post-ablation BE recurrence using itraconazole, are discussed.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.